论文部分内容阅读
Objective: To investigate the association of a common 5G/4G polymorphism of the plasminogen activator inhibitor-1 gene (PAI1) with occurrence and clinical characteristics of the polycystic ovary syndrome (PCOS). Study design: In a case-control study, we evaluated a series of 106 Caucasian women with PCOS and 102 healthy controls. Women completed a detailed questionnaire and underwent a peripheral venous puncture, ultrasonography, and a standardized oral glucose tolerance test (OGTT).The PAI1 gene promoter polymorphism was evaluated using PCR. Results: Allele and genotype frequencies were not significantly different among women with PCOS and controls (P = 0.3 and 0.6, respectively). In women with PCOS, presence of the 5G/4G polymorphism of PAI1 was not associated with changes in serum hormone levels or with clinical characteristics. Conclusions: The 5G/4G polymorphism of the PAI1 promoter is not associated with occurrence and phenotype of the PCOS.
Objective: To investigate the association of a common 5G / 4G polymorphism of the plasminogen activator inhibitor-1 gene (PAI1) with occurrence and clinical characteristics of the polycystic ovary syndrome (PCOS). Study design: In a case-control study, we are evaluated as a series of 106 women with PCOS and 102 healthy controls. Women completed a detailed questionnaire and underwent a peripheral venous puncture, ultrasonography, and a standardized oral glucose tolerance test (OGTT). PAI1 gene promoter polymorphism was evaluated using PCR. Allele and genotypes were not significantly different among women with PCOS and controls (P = 0.3 and 0.6, respectively). In women with PCOS, presence of the 5G / 4G polymorphism of PAI1 was not associated with changes in serum hormone levels or with clinical Conclusions: The 5G / 4G polymorphism of the PAI1 promoter is not associated with occurrence and phenotype of the PCOS.